Amplia Therapeutics with CEO Chris Burns

00:00 – Intro & welcome to Chris Burns, CEO of Amplia02:00 – Why pancreatic cancer is so deadly & hard to diagnose06:30 – Current treatment options: Gem/Abraxane vs FOLFIRINOX11:20 – Side effects & challenges with chemotherapy15:00 – Why pancreatic cancer is difficult to treat (fibrosis & mutations)19:00 – Amplia’s approach: FAK inhibitors and how they work23:00 – History of FAK inhibitors & Amplia’s drug development story27:00 – ACCENT trial design and early results (response rate, PFS)32:00 – Complete responses & long-term responders (12–18+ months)36:00 – Next steps: Simplicity trial with FOLFIRINOX38:30 – Path to registrational trial & FDA fast track41:00 – Combination opportunities: KRAS inhibitors & ADCs43:00 – Commercial strategy, pricing, partnerships44:30 – Wrap-up & final thoughts